Tyra Biosciences Financial Statements
NASDAQ: TYRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
19.94-0.03 (-0.15%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tyra Biosciences revenue and earnings
Tyra Biosciences reported a net loss of $119.9 million, compared with a loss of $86.5 million a year earlier. Diluted earnings per share came in at -$2.01.
Summary generated from market data by MetaCap's automated system. Methodology
Tyra Biosciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Operating Expenses | 132.76M | 104.18M | 79.94M | 58.93M | 26.29M | 9.30M |
| Research & Development | 102.93M | 80.08M | 62.52M | 43.01M | 20.64M | 7.20M |
| Operating Income | -132.76M | -104.18M | -79.94M | -58.93M | -26.29M | -9.30M |
| Other Income (Expense) | 12.81M | 17.70M | 10.81M | 3.60M | -6.00K | -39.00K |
| Income Tax | 0 | 0 | 0 | 2.00K | 1.00K | 1.00K |
| Net Income | -119.95M | -86.48M | -69.13M | -55.33M | -26.29M | -9.34M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -2.01 | -1.51 | -1.62 | -1.32 | -1.91 | -6.05 |
| EPS (Diluted) | -2.01 | -1.51 | -1.62 | -1.32 | -1.91 | -6.05 |
| Shares Outstanding (Basic) | 59.60M | 57.22M | 42.70M | 41.88M | 13.78M | 1.54M |
| Shares Outstanding (Diluted) | 59.60M | 57.22M | 42.70M | 41.88M | 13.78M | 1.54M |
| EBITDA | -132.22M | -103.66M | -79.59M | -58.63M | -26.15M | -9.25M |
This table shows 6 annual periods of Tyra Biosciences's income statement, from FY 2025 back to FY 2020, across 11 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow TYRA's reporting calendar. What is a income statement?